Altruist Biologics Congratulates Partner LongBio Pharma on the BLA Acceptance of LP-003 by the China NMPA
Enabled by Altruist's integrated CMC development platform, GMP manufacturing and regulatory service capabilities, LP-003 has successfully advanced from concept to potential commercialization. LP-003 is the first innovative drug independently...
Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
First antibody-drug conjugate facility to receive three provincial regulatory approvals for segmented manufacturing. Demonstrated a unified quality system, strict risk assessment protocols, and compliance with rigorous regulatory requirements from...